Predictors of discontinuing overactive bladder medications

BJU International

Volumn 105, Issue 9, 2010, Pages 1283-1290

  Brubaker, Linda ^a   Fanning, Kristina ^b   Goldberg, Erica L ^c   Benner, Joshua S ^c,d   Trocio, Jeffrey N ^e   Bavendam, Tamara ^e   Jumadilova, Zhanna ^e  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b Vedanta Associates Inc   (United States)

^c IQVIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e PFIZER INC   (United States)

Author keywords

Compliance; Overactive bladder; Persistence; Predictors

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT;

ACCESS TO INFORMATION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH BEHAVIOR; HEALTH BELIEF; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PATIENT EDUCATION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; SELF REPORT; SMOKING; UNITED STATES; URGE INCONTINENCE;

ADOLESCENT; ADULT; AGED; ATTITUDE TO HEALTH; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; UNITED STATES; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 77950825721     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09035.x     Document Type: Article

References (24)

1. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn 2006 25 : 293
2. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20 : 327 336 (Pubitemid 44175300)
3. Hu TW, Wagner TH, Bentkover JD et al. Estimated economic costs of overactive bladder in the United States. Urology 2003 61 : 1123 1128 (Pubitemid 36693985)
4. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008 101 : 1388 1395 (Pubitemid 351623990)
5. Andersson K-E. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 2004 3 : 46 53
6. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008 54 : 543 562
7. Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology 2006 68 (Suppl. 38 48 (Pubitemid 44189489)
8. Varadharajan S, Jumadilova Z, Girase P, Ollendorf DA. Economic impact of extended-release tolterodine versus immediate- and extended- release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care 2005 11 (Suppl. S140 9 (Pubitemid 41022722)
9. Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California medicaid program. Value Health 2005 8 : 495 505 (Pubitemid 41726103)
10. Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z. Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005 11 (Suppl. S121 9 (Pubitemid 41022720)
11. Krueger KP, Berger BA, Felkey B. Medication adherence and persistence: a comprehensive review. Adv Ther 2005 22 : 313 356 (Pubitemid 43003324)
12. Noe L, Sneeringer R, Patel B, Williamson T. The implications of poor medication persistence with treatment for overactive bladder. Manag Care Interface 2004 17 : 54 60 (Pubitemid 40444166)
13. Benner JS, Becker R, Fanning K, Jumadilova Z, Bavendam T, Brubaker L. Bother related to bladder control and healthcare-seeking behavior in US adults. J Urol 2009 181 : 2591 2598
14. Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 2005 22 : 381 394 (Pubitemid 43003328)
15. Balkrishnan R, Bhosle MJ, Camacho FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. J Urol 2006 175 : 1067 1071 (Pubitemid 43200091)
16. Hannestad YS, Rortveit G, Daltveit AK, Hunskaar S. Are smoking and other lifestyle factors associated with female urinary incontinence? The Norwegian EPINCONT Study. BJOG 2003 110 : 247 254 (Pubitemid 36298906)
17. Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioral interventions in the treatment of overactive bladder and urinary incontinence. Int J Clin Prac 2009 63 : 1177 1191
18. Herschorn S, Becker D, Miller E, Thompson M, Forte L. Impact of a health education intervention in overactive bladder patients. Can J Urol 2004 11 : 2430 2437
19. Klutke CG, Burgio KL, Wyman JF et al. Combined effects of behavioral intervention and tolterodine in subjects dissatisfied with their overactive bladder medication. J Urol 2009 181 : 2599 2607
20. Benner JS, Nichol MB, Rovner ES et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2009 (in press)
21. Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z. Fesoterodine dose-response in subjects with overactive bladder syndrome. Urology 2008 71 : 839 843
22. D'Souza AO, Smith MJ, Miller LA, Doyle J, Ariely R. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharma 2008 14 : 291 301 (Pubitemid 351711980)
23. Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol 2008 112 : 1311 1318
24. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 353 : 487 497 (Pubitemid 41127293)